Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The state-of-the-art digital PETCT imaging system, highlights a significant advancement in the fight against cancer and detects other lesions offering patient centric services
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Marks the World Head & Neck Cancer Day at the OCTF Conference
Subscribe To Our Newsletter & Stay Updated
